Bellerophon to Participate in LEERINK Partners 5th Annual Global Healthcare Conference

WARREN, N.J., Feb. 03, 2016 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it will participate in LEERINK Partners 5^th Annual Global Healthcare Conference.

Jonathan Peacock, Bellerophon’s Chairman and Chief Executive Officer, will take questions during a fireside chat at 10:40 am ET on Wednesday, February 10, 2016.

A live webcast may be accessed under the investor tab at www.bellerophon.com. An archive of the presentation will be available following the presentation.

About Bellerophon

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. The Company is currently developing two product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company intends to commence Phase 3 clinical trials shortly and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase 2 development. The Company is also planning to start testing the benefits of INOpulse for patients suffering from pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) for which results are anticipated by the end of 2016. For more information, please visit www.bellerophon.com.

Contact
At Bellerophon:
Amy Edmonds, Vice President
Head of Clinical Operations &
Administration
(908) 574-4765

At Rx Communications Group:
Melody Carey
(917) 322-2571
[email protected]